Norman T. Ilowite

Norman T. Ilowite

Auto-generated profile, based on publicly available information

Norman T. Ilowite

Albert Einstein College of Medicine and Children's Hospital at Montefiore, Bronx, New York

Research Focus & Metrics

Academic Career Length

38Years (1989-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 March 2011 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
TBTimothy Beukelman
Timothy Beukelman
NPNivedita M. Patkar
Nivedita M. Patkar
KSKenneth G. Saag
Kenneth G. Saag
STSue Tolleson‐Rinehart
Sue Tolleson‐Rinehart
RCRandy Q. Cron
Randy Q. Cron
NRNicolino Ruperto
Nicolino Ruperto
Click on the article title to read more.

28 January 2011 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
PNPeter A. Nigrovic
Peter A. Nigrovic
MMMelissa Mannion
Melissa Mannion
FPFemke H. M. Prince
Femke H. M. Prince
AZAndrew Zeft
Andrew Zeft
CRC. Egla Rabinovich
C. Egla Rabinovich
GHGloria C. Higgins
Gloria C. Higgins

27 February 2007 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
JBJack Bleesing
Jack Bleesing
APAnne Prada
Anne Prada
DSDavid M. Siegel
David M. Siegel
JVJoyce Villanueva
Joyce Villanueva
JOJudyann Olson
Judyann Olson
AGAlexei A. Grom
Alexei A. Grom

19 December 2011 in Arthritis & Rheumatism
Verified
Journal Article
Open access
PDF file
CWCarol A. Wallace
Carol A. Wallace
EGEdward H. Giannini
Edward H. Giannini
SSSteven J. Spalding
Steven J. Spalding
PHPhilip J. Hashkes
Philip J. Hashkes
KOKathleen M. O'Neil
Kathleen M. O'Neil
FAfor the Childhood Arthritis and Rheumatology Research Alliance
for the Childhood Arthritis and Rheumatology Research Alliance
Objective: To determine whether aggressive treatment initiated early in the course of rheumatoid factor (RF)–positive or RF‐negative polyarticular juvenile idiopathic arthritis (JIA) can induce clinical inactive disease within 6 months.Methods: Between May 2007 and October 2010, a multicenter, prospective, randomized, double‐blind, placebo‐controlled trial of 2 aggressive treatments was conducted in 85 children ages 2–16 years with polyarticular JIA of <12 months' duration. Patients received either methotrexate (MTX) 0.5 mg/kg/week (maximum 40 mg) subcutaneously, etanercept 0.8 mg/kg/week (maximum 50 mg), and prednisolone 0.5 mg/kg/day (maximum 60 mg) tapered to 0 by 17 weeks (arm 1), or MTX (same dosage as arm 1), etanercept placebo, and prednisolone placebo (arm 2). The primary outcome measure was clinical inactive disease at 6 months. An exploratory phase determined the rate of clinical remission on medication (6 months of continuous clinical inactive disease) at 12 months.Results: By 6 months, clinical inactive disease had been achieved in 17 (40%) of 42 patients in arm 1 and 10 (23%) of 43 patients in arm 2 (χ2 = 2.91, P = 0.088). After 12 months, clinical remission on medication was achieved in 9 patients in arm 1 and 3 patients in arm 2 (P = 0.053). There were no significant interarm differences in adverse events.Conclusion: Although this study did not meet its primary end point, early aggressive therapy in this cohort of children with recent‐onset polyarticular JIA resulted in clinical inactive disease by 6 months and clinical remission on medication within 12 months of treatment in substantial proportions of patients in both arms.

25 April 2008 in Arthritis & Rheumatism
Verified
Journal Article
Closed access
PDF file
DLDaniel Joe Lovell
Daniel Joe Lovell
ARAndreas Reiff
Andreas Reiff
NINorman T. Ilowite
Norman T. Ilowite
CWCarol A. Wallace
Carol A. Wallace
YCYun Chon
Yun Chon
PGPediatric Rheumatology Collaborative Study Group
Pediatric Rheumatology Collaborative Study Group

30 January 2012 in Arthritis Care & Research
Verified
Journal Article
Open access
PDF file
EDEsi Morgan Dewitt
Esi Morgan Dewitt
YKYukiko Kimura
Yukiko Kimura
TBTimothy Beukelman
Timothy Beukelman
PNPeter A. Nigrovic
Peter A. Nigrovic
KOKaren Onel
Karen Onel
OAon behalf of the Juvenile Idiopathic Arthritis Disease‐specific Research Committee of the Childhood Arthritis Rheumatology and Research Alliance
on behalf of the Juvenile Idiopathic Arthritis Disease‐specific Research Committee of the Childhood Arthritis Rheumatology and Research Alliance
Objective: There is wide variation in therapeutic approaches to systemic juvenile idiopathic arthritis (JIA) among North American rheumatologists. Understanding the comparative effectiveness of the diverse therapeutic options available for treatment of systemic JIA can result in better health outcomes. The Childhood Arthritis and Rheumatology Research Alliance (CARRA) developed consensus treatment plans and standardized assessment schedules for use in clinical practice to facilitate such studies.Methods: Case‐based surveys were administered to CARRA members to identify prevailing treatments for new‐onset systemic JIA. A 2‐day consensus conference in April 2010 employed modified nominal group technique to formulate preliminary treatment plans and determine important data elements for collection. Followup surveys were employed to refine the plans and assess clinical acceptability.Results: The initial case‐based survey identified significant variability among current treatment approaches for new‐onset systemic JIA, underscoring the utility of standardized plans to evaluate comparative effectiveness. We developed 4 consensus treatment plans for the first 9 months of therapy, as well as case definitions and clinical and laboratory monitoring schedules. The 4 treatment regimens included glucocorticoids only, or therapy with methotrexate, anakinra, or tocilizumab, with or without glucocorticoids. This approach was approved by >78% of the CARRA membership.Conclusion: Four standardized treatment plans were developed for new‐onset systemic JIA. Coupled with data collection at defined intervals, use of these treatment plans will create the opportunity to evaluate comparative effectiveness in an observational setting to optimize initial management of systemic JIA.